Field
     Antibody Drug, Medicinal Drug

Keywords
     Anticancer,  Breast Cancer, Human Tenascin C, Anti-TNIIIA2 Antibody

Advantages
     Anti-TNIIIA2 Ab makes "AOIKIS".
     Anti-TNIIIA2 Ab prohibits hyper-stimulation of proliferation(focus formation).
     Anti-TNIIIA2 Ab prohibits tumor cell invasion.
     Anti-TNIIIA2 Ab prohibits the epithelial-mesenchymal transition(EMT).
     Therefore it will be useful and act as anti-cancer drug REFERENCE:LSP52.

Abstract
Provided are a remedy for chronic inflammation which comprises an antibody capable of recognizing a peptide (TNIIIA2) derived from partial sequence A2 of human Tenascin-C fibronectin III-like repeats; and the anti-TNIIIA2 antibody to be used therein.
Because an amino-acid sequence (TNIIIA2) as a cell-adhesive substrate in Tenascin exclusively plays a critical role, an antibody to its active site has been produced. The antibody has been able to be used for treating chronic inflammation by blocking the function of TNIIIA2. Then, we filed patent applications for the antibody and for its therapeutic use. After these applications, we filed additional patent applications have been made since there is the possibility of using it for other purposes.
Tenascin has been focused on and studied by many companies, the majority of which were unable to discover the most important part of its function and have given up their studies of it.

        

Inventor
     Prof. Fumio Fukai et al.　(Tokyo University of Science)



Patent Publication No
     (APPLICATION NUMBER, FILING DATE) *Not yet published
     JP2010-170975（Jul. 29, 2010） 

To access the rest of the information on this page,
Log In or sign up for a free B-Bridge account: